Company intelligence / Profile preview

HEFRIN

Ownership: Private
Development stage: Other

Overview

Hefrin is a biotechnology company focused on the development of novel therapeutic agents targeting heparanase, an enzyme involved in the degradation of the extracellular matrix. The company's research primarily centers on the role of heparanase in cancer progression, metastasis, and inflammatory diseases. By inhibiting this enzyme, Hefrin aims to provide new treatment options for various solid tumors and chronic inflammatory conditions. The company is currently in the pre-clinical stage, advancing its lead candidates through early-stage validation and optimization.

Therapeutic areas: NephrologyOncologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on HEFRIN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEFRIN.

Explore the full profile